GNMLF Quote, Financials, Valuation and Earnings

Corporativo Fragua SAB de CV has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of --. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat Corporativo Fragua SAB de CV's return on equity of --.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Corporativo Fragua SAB de CV has an analysts' consensus of -- which suggests that it could fall by --. Given that Genomma Lab Internacional SAB de CV has higher upside potential than Corporativo Fragua SAB de CV, analysts believe Genomma Lab Internacional SAB de CV is more attractive than Corporativo Fragua SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.121, which suggesting that the stock is 87.883% less volatile than S&P 500. In comparison Corporativo Fragua SAB de CV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 3.96%. Corporativo Fragua SAB de CV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. Corporativo Fragua SAB de CV pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than Corporativo Fragua SAB de CV quarterly revenues of --. Genomma Lab Internacional SAB de CV's net income of $23.3M is higher than Corporativo Fragua SAB de CV's net income of --. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 11.57x while Corporativo Fragua SAB de CV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.12x versus -- for Corporativo Fragua SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of --. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat CEL-SCI Corp.'s return on equity of -230.36%.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 707.99%. Given that CEL-SCI Corp. has higher upside potential than Genomma Lab Internacional SAB de CV, analysts believe CEL-SCI Corp. is more attractive than Genomma Lab Internacional SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.121, which suggesting that the stock is 87.883% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 3.96%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than CEL-SCI Corp. quarterly revenues of --. Genomma Lab Internacional SAB de CV's net income of $23.3M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 11.57x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.12x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of -953.4%. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1277.04%. Given that IGC Pharma, Inc. has higher upside potential than Genomma Lab Internacional SAB de CV, analysts believe IGC Pharma, Inc. is more attractive than Genomma Lab Internacional SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.121, which suggesting that the stock is 87.883% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.78%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 3.96%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Genomma Lab Internacional SAB de CV's net income of $23.3M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 11.57x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.12x versus 21.12x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of -255.85%. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than Genomma Lab Internacional SAB de CV, analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than Genomma Lab Internacional SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.121, which suggesting that the stock is 87.883% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 3.96%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Genomma Lab Internacional SAB de CV's net income of $23.3M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 11.57x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.12x versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.